Sentences with phrase «clinical vaccines studies»
Therefore the group: i) characterizes the specificity of these antibody responses to identify relevant targets for a vaccine; ii) developes new approaches to test antibody responses; and iii) adoptes the immunological analysis in preclinical (in rabbits and macaques) and clinical vaccines studies to identify predictive signatures for the development and prioritization of new HIV - 1 vaccine candidates.
http://research.hsr.it/ Not exact matches
Inovio's vaccine against HPV is currently in Phase II clinical studies, and Kim says «about 50 percent» of the subjects in that trial are defeating the disease.
But while thousands of clinical trials on immunotherapy drugs, of which many are predicted to fail, are springing up, the depth of information on neoantigen vaccines is much shallower: Just two studies on neoantigen vaccines for melanoma, recently profiled in Nature, were completed last year in Boston and Germany.
The study, «The efficacy of the BCG vaccine against newly emerging clinical strains of Mycobacterium tuberculosis,» was published in the journal PLOS One in September.
The study caught the attention of vaccine maker Sanofi Pasteur, which plans to test the vaccine in clinical trials.
«This vaccine appears to be safe for patients, and elicits a broad anti-tumor immunity — we think it warrants further testing in larger clinical trials,» said study lead author Janos L. Tanyi, MD, an assistant professor of obstetrics and gynecology at Penn Medicine.
«We are pleased to have demonstrated such a potent and durable immune response to the vaccine,» said the study's lead author, Sita Awasthi, PhD, a research associate professor of Infectious Diseases at Penn. «If found effective in clinical trials, the vaccine will have a huge impact on reducing the overall prevalence of genital herpes infections and could reduce new HIV infections as well, especially in high - burden regions of sub-Saharan Africa.»
But vaccines that only contained HIV's surface protein looked lackluster in animal and test tube studies, and then proved worthless in large - scale clinical trials.
«Delivery of the HPV vaccine in safety - net settings is critically important because uninsured African - American and Hispanic women have higher rates of cervical cancer,» said Dr. Jasmin Tiro, Associate Professor of Clinical Sciences at UT Southwestern, who led the study.
Study data also indicated that the high - dose vaccine may provide clinical benefit for the prevention of hospitalizations, pneumonia, cardio - respiratory conditions, non-routine medical visits, and medication use.
The study included 124 newly diagnosed patients at 25 clinical trial sites in the U.S. Two - thirds of the patients were treated with ICT - 107, an experimental vaccine based on immune system cells called dendritic cells that were exposed to six synthetic proteins, or antigens, known to be involved in GBM development.
The Swiss - based pharmaceutical company said that it had made 10 liters of vaccine that it will use in pre-clinical studies and maybe early clinical trials.
CureVac's most advanced project is a prostate cancer therapy that is now entering a second phase II clinical study; a vaccine against rabies is in phase I tests.
«The idea behind this study was to re-evaluate the bar that was previously established for evaluating a person's immune response to influenza vaccines,» said the study's principal investigator Matthew J. Memoli, M.D., director of the Clinical Studies Unit in NIAID's Laboratory of Infectious Diseases.
To address that debate, Kojic's study, dubbed «AIDS Clinical Trials Group Protocol 5240,» measured the safety and immune system response of the vaccine in HIV - positive women aged 13 to 45 with a wide range of immune statuses.
Co-administration of the 9 - valent HPV vaccine with diphtheria, tetanus, pertussis, polio, and meningococcal vaccines could also be completed at the same visit, which has been demonstrated in clinical studies.
The data obtained from this study provide a basis for more rapid, cost - effective clinical trials to evaluate new influenza drugs or to determine the efficacy of candidate vaccines for both seasonal and pandemic influenza.
The vaccine is in its first stage of clinical safety's studies, which proved to have a relatively weak effect.
Just a few weeks ago, WHO said that using any of the experimental drugs or vaccines in the pipeline simply wasn't in the cards, because none of them have been through a phase I clinical study, the type of trial in which medical products are tested on healthy volunteers to study their toxicity.
Due to major advances in their immune potency DNA vaccines are being studied in human clinical trials for treating cancer and infectious diseases.
The Pilot Bioproduction Facility headed by Dr. Kenneth H. Eckels, produced small batches of vaccine candidates that were used for the preclinical studies and is currently manufacturing a vaccine lot for use in initial human clinical studies.
Vaccine developers are trying to improve vaccines for transplant recipients and other people with a weak immune system, and the samples used in this study came from a clinical trial of different versions of a flu vaccine in patients on immune - suppressiveVaccine developers are trying to improve vaccines for transplant recipients and other people with a weak immune system, and the samples used in this study came from a clinical trial of different versions of a flu vaccine in patients on immune - suppressivevaccine in patients on immune - suppressive drugs.
But a new animal study shows that the vaccine performs much better when given intravenously instead of into the skin, as it was in the clinical trial.
When a biotech company called Sanaria presented the results of a clinical study of its unconventional malaria vaccine last year, many researchers were disappointed.
A study of 4CMenB, a new vaccine to protect against meningitis B bacteria (which can cause potentially fatal bacterial meningitis in children), shows that waning immunity induced by infant vaccination can be overcome by a booster dose at 40 months of age, according to a clinical trial published in CMAJ (Canadian Medical Association Journal).
«In line with our company's commitment to address global health needs, we are committed to working with leading experts to develop a preventative HIV vaccine and our team is excited to advance this program into human clinical studies.»
The findings of this study provide the basis for advancing this experimental vaccine to an NIH phase I clinical study.
An HIV - 1 version of the promising vaccine regimen is now being evaluated in an ongoing Phase 1 / 2a international clinical study.
Based on these pre-clinical data, the HIV - 1 version of this vaccine regimen is now being evaluated in an ongoing Phase 1 / 2a international clinical study sponsored by Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
The agency approved the vaccines with scant clinical data, relying instead on the same «strain change» rules that allow manufacturers to change the seasonal vaccine without conducting human studies.
The study, «The efficacy of the BCG vaccine against newly emerging clinical strains of Mycobacterium tuberculosis,» was published in September.
The next steps for this vaccine are to produce a clinical grade lot and conduct a phase 1 study of safety and immunogenicity in infants, Moore says.
Phase II trial - an intermediate clinical trial for studying an experimental vaccine in humans.
Phase I trial - an early clinical trial designed to study an experimental vaccine in humans.
SEATTLE, WA and DURHAM, NC — The HIV Vaccine Trials Network (HVTN) and the HIV Prevention Trials Network (HPTN) today announced the initiation of HVTN 704 / HPTN 085, also known as Antibody Mediated Prevention (AMP) or the AMP Study, a Phase 2b clinical trial to evaluate the safety and efficacy of VRC01, a broadly neutralizing monoclonal antibody (bnAb).
The assay will be validated against clinical outcomes in human vaccine studies (correlates of protection such as neutralising antibodies or vaccine - induced protection in human challenge models, or exploratory correlates such as multifunctional Th1 cells).
A feasibility study: association between gut microbiota enterotype and antibody response to seasonal trivalent influenza vaccine in adults — Nick Shortt — Clinical and Translational Immunology
The Pilot Bioproduction Facility at WRAIR manufactured the ZPIV vaccine being used in Phase 1 clinical studies, and the Army recently signed a cooperative research and development agreement to transfer the ZPIV technology to Sanofi Pasteur to explore larger scale manufacturing and advanced development.
This experimental vaccine regimen is based on the one tested in the U.S. Military HIV Research Program - led RV144 clinical trial in Thailand — the first study to demonstrate that a vaccine can protect people from HIV infection.
Moderna's Zika mRNA vaccine, mRNA - 1325, is currently in Phase 1/2 clinical study in healthy volunteers.
Our broad technological capabilities can guide your innovative vaccine concept through the development chain, bridging the gap between early discovery and late stage clinical studies.
According to Col Jerome Kim, Walter Reed Army Institute of Research, US, who was also part of the lead group for the study, apart from the current four doses of vaccines that were given to subjects in the phase III clinical trials in Thailand, they are planning to give a booster does after six months to increase the strength of the vaccine.
CAMBRIDGE, Mass., April 27, 2017 — Moderna Therapeutics, a clinical stage biotechnology company that is pioneering messenger RNA (mRNA) Therapeutics ™ to create a new generation of transformative medicines for patients, today announced positive interim data from an ongoing Phase 1 study of mRNA - 1440, an mRNA infectious disease vaccine against avian H10N8 influenza, demonstrating mRNA - 1440 induced high levels of immunogenicity, and was safe and well tolerated.
Because of this unique talent, DCs are now a major focus of laboratory and clinical study across the globe, and are critical targets in cancer vaccine development.
A malaria vaccine has shown promising results in early stage clinical trials, a study suggests.
MHRP's international research program has six clinical research sites in the U.S., Africa and Asia, where it conducts HIV cohort studies, HIV vaccine trials and therapeutic studies.
Follow - up clinical studies using modified vaccine regimens and extra boosts are set to begin in Southern Africa in 2015.
Building on the findings of an earlier study that found for the first time, albeit modestly, that a vaccine could prevent HIV infection in 2016, an NIH - supported clinical trial was launched to test a modified HIV vaccine.
A new UC San Francisco study has shown that a cancer - killing («oncolytic») virus currently in clinical trials may function as a cancer vaccine — in addition to killing some cancer cells directly, the virus alerts the immune system to the presence of a tumor, triggering a powerful, widespread immune response that kills cancer cells far outside the virus - infected region.
Several clinical studies of cancer vaccines for colorectal cancer are open, including: